<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-240-8-5-12</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-3408</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Факторы риска тяжелого фиброза при неалкогольной жировой болезни печени, ассоциированной с сахарным диабетом 2 типа</article-title><trans-title-group xml:lang="en"><trans-title>Risk factors of advanced fibrosis in non-alcoholic fatty liver disease, associated with type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6392-8461</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корой</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Koroy</surname><given-names>P. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5727-1640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ягода</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yagoda</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7590-6201</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демурчева</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Demurcheva</surname><given-names>E. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7244-3507</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудов</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudov</surname><given-names>T. R.</given-names></name></name-alternatives><email xlink:type="simple">timur222123@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение здравоохранения Ставропольского края «Краевой эндокринологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Endocrinological Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2026</year></pub-date><volume>0</volume><issue>8</issue><fpage>5</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Корой П.В., Ягода А.В., Демурчева Е.О., Дудов Т.Р., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Корой П.В., Ягода А.В., Демурчева Е.О., Дудов Т.Р.</copyright-holder><copyright-holder xml:lang="en">Koroy P.V., Yagoda A.V., Demurcheva E.O., Dudov T.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/3408">https://www.nogr.org/jour/article/view/3408</self-uri><abstract><p>Цель исследования. Изучить факторы риска тяжелого фиброза при неалкогольной жировой болезни печени (НАЖБП), ассоциированной с сахарным диабетом 2 типа, во взаимосвязи с содержанием витамина D в крови. Материалы и методы. Обследован 171 больной НАЖБП и сахарным диабетом 2 типа (140 женщин, 31 мужчина), в возрасте от 31 до 69 лет. Сывороточные уровни витамина D определялись методом твердофазного иммуноферментного анализа. Выраженность фиброза печени оценивалась с помощью транзиентной эластометрии. Результаты. У больных НАЖБП, ассоциированной с сахарным диабетом 2 типа, фиброз печени F3-4 выявлен в 14,1% случаев и был связан с показателями окружности талии ≥ 118 см, уровнями тромбоцитов ≤ 225х109/л, общего холестерина ≥ 7,92 ммоль/л, триглицеридов ≥ 2,5 ммоль/л, гаммаглютамилтранспептидазы (ГГТ) ≥ 37 ед/л, щелочной фосфатазы ≥ 64 ед/л, прямого билирубина ≤ 1,3 мкмоль/л, витамина D ≤ 13,0 нг/мл, а также с наличием гипертриглицеридемии. По данным многофакторного регрессионного анализа, независимыми предикторами фиброза печени F3-4 были содержание в крови ГГТ, триглицеридов, тромбоцитов и витамина D. Комбинация этих признаков в прогнозировании тяжелого фиброза/цирроза имела чувствительность 70,8% и специфичность 95,6%. Заключение. Таким образом, уровни триглицеридов, тромбоцитов и витамина D в крови, а также активность ГГТ ассоциированы с фиброзом F3-4 при НАЖБП у больных сахарным диабетом 2 типа, что, надо полагать, связано с их участием в процессах повреждения, воспаления и фиброгенеза печени.</p></abstract><trans-abstract xml:lang="en"><p>Aim of the investigation. To study the risk factors of advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus in relation to the vitamin D content in the blood. Materials and methods. 171 patients with NAFLD and type 2 diabetes mellitus (140 women, 31 men), aged from 31 to 69 years, were examined. Serum vitamin D levels were determined by enzyme-linked immunosorbent assay. The severity of liver fibrosis was assessed using transient elastometry. Results. In patients with NAFLD associated with type 2 diabetes mellitus liver fibrosis F3-4 was detected in 14.1% of cases and was associated with parameters of waist circumference ≥ 118 cm, platelets ≤ 225x109/l, total cholesterol ≥ 7.92 mmol/l, triglycerides ≥ 2.5 mmol/L, gammaglutamyltranspeptidase (GGT) ≥ 37 un/l, alkaline phosphatase ≥ 64 u/l, direct bilirubin ≤ 1.3 mmol/l, vitamin D ≤ 13.0 ng/ml, as well as the presence of hypertriglyceridemia. According to multivariate regression analysis, independent predictors of liver fibrosis F3-4 were blood levels of GGT, triglycerides, platelets, and vitamin D. The combination of these parameters in predicting of advanced fibrosis/cirrhosis had a sensitivity of 70.8% and a specificity of 95.6%. Conclusion. Thus, blood levels of triglycerides, platelets, and vitamin D, as well as GGT activity, were associated with fibrosis F3-4 in patients with NAFLD and type 2 diabetes mellitus, that, probably, is connected with their involvement in liver damage, inflammation, and fibrogenesis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>фиброз печени</kwd><kwd>витамин D</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>liver fibrosis</kwd><kwd>vitamin D</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024; 67 (11): 2375-2392. doi: 10.1007/s00125-024-06258-6.</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024; 67 (11): 2375-2392. doi: 10.1007/s00125-024-06258-6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wong V.-S., Ekstedt M., Wong G.-H. et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 2023; 79 (3): 842-852. doi: 10.1016/j.jhep.2023.04.036.</mixed-citation><mixed-citation xml:lang="en">Wong V.-S., Ekstedt M., Wong G.-H. et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 2023; 79 (3): 842-852. doi: 10.1016/j.jhep.2023.04.036.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Castera L., Cusi K. Diabetes and cirrhosis: current concepts on diagnosis and management. Hepatology. 2023; 77 (6): 2128-2146. doi: 10.1097/HEP.0000000000000263.</mixed-citation><mixed-citation xml:lang="en">Castera L., Cusi K. Diabetes and cirrhosis: current concepts on diagnosis and management. Hepatology. 2023; 77 (6): 2128-2146. doi: 10.1097/HEP.0000000000000263.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Demir M., Deyneli O., Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: a transient elastography study. Turk. J. Gastroenterol. 2019; 30: 266-270. doi: 10.5152/tjg.2018.18559.</mixed-citation><mixed-citation xml:lang="en">Demir M., Deyneli O., Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: a transient elastography study. Turk. J. Gastroenterol. 2019; 30: 266-270. doi: 10.5152/tjg.2018.18559.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Diaconu C. T., Guja C. Nonalcoholic fatty liver disease and its complex relation with type 2 diabetes mellitus-from prevalence to diagnostic approach and treatment strategies. J. Clin. Med. 2022; 11 (17): 5144. doi: 10.3390/jcm11175144.</mixed-citation><mixed-citation xml:lang="en">Diaconu C. T., Guja C. Nonalcoholic fatty liver disease and its complex relation with type 2 diabetes mellitus-from prevalence to diagnostic approach and treatment strategies. J. Clin. Med. 2022; 11 (17): 5144. doi: 10.3390/jcm11175144.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ajmera V., Cepin S., Tesfai K. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 2023; 78 (3): 471-478. doi: 10.1016/j.jhep.2022.11.010.</mixed-citation><mixed-citation xml:lang="en">Ajmera V., Cepin S., Tesfai K. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 2023; 78 (3): 471-478. doi: 10.1016/j.jhep.2022.11.010.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Castera L., Laouenan C., Vallet-Pichard A. et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes. Care. 2023; 46 (7): 1354-1362. doi: 10.2337/dc22-2048.</mixed-citation><mixed-citation xml:lang="en">Castera L., Laouenan C., Vallet-Pichard A. et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes. Care. 2023; 46 (7): 1354-1362. doi: 10.2337/dc22-2048.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Luukkonen P. K., Qadri S., Ahlholm N. et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J. Hepatol. 2022; 76 (3): 526-535. doi: 10.1016/j.jhep.2021.10.013.</mixed-citation><mixed-citation xml:lang="en">Luukkonen P. K., Qadri S., Ahlholm N. et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J. Hepatol. 2022; 76 (3): 526-535. doi: 10.1016/j.jhep.2021.10.013.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hatano Y., VanWagner L. B., Carnethon M. R. et al. Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study. Diabetologia. 2023; 66 (7): 1235-1246. doi: 10.1007/s00125-023-05903-w.</mixed-citation><mixed-citation xml:lang="en">Hatano Y., VanWagner L. B., Carnethon M. R. et al. Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study. Diabetologia. 2023; 66 (7): 1235-1246. doi: 10.1007/s00125-023-05903-w.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Oh J., Riek A. E., Bauerle K. T. et al. Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes. Nat.Commun. 2023; 14 (1): 3278. doi: 10.1038/s41467-023-38849-z.</mixed-citation><mixed-citation xml:lang="en">Oh J., Riek A. E., Bauerle K. T. et al. Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes. Nat.Commun. 2023; 14 (1): 3278. doi: 10.1038/s41467-023-38849-z.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Taderegew M. M., Woldeamanuel G. G., Wondie A. et al. Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMJ Open. 2023; 13: e075607. doi: 10.1136/bmjopen-2023-075607.</mixed-citation><mixed-citation xml:lang="en">Taderegew M. M., Woldeamanuel G. G., Wondie A. et al. Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMJ Open. 2023; 13: e075607. doi: 10.1136/bmjopen-2023-075607.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X., Wan Z., Geng T. et al. Vitamin D status, vitamin D receptor polymorphisms, and risk of microvascular complications among individuals with type 2 diabetes: a prospective study. Diabetes. Care. 2023; 46 (2): 270-277. doi: 10.2337/dc22-0513.</mixed-citation><mixed-citation xml:lang="en">Chen X., Wan Z., Geng T. et al. Vitamin D status, vitamin D receptor polymorphisms, and risk of microvascular complications among individuals with type 2 diabetes: a prospective study. Diabetes. Care. 2023; 46 (2): 270-277. doi: 10.2337/dc22-0513.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan S., Larsson S. C. Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2023; 21: 398-405. doi: 10.1016/j.cgh.2022.01.021.</mixed-citation><mixed-citation xml:lang="en">Yuan S., Larsson S. C. Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2023; 21: 398-405. doi: 10.1016/j.cgh.2022.01.021.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Saberi B., Dadabhai A. S., Nanavati J. et al. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: a PRISMA compliant systematic review and meta-analysis of pooled data. World J. Hepatol. 2018; 10 (1): 142-154. doi: 10.4254/wjh.v10.i1.142.</mixed-citation><mixed-citation xml:lang="en">Saberi B., Dadabhai A. S., Nanavati J. et al. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: a PRISMA compliant systematic review and meta-analysis of pooled data. World J. Hepatol. 2018; 10 (1): 142-154. doi: 10.4254/wjh.v10.i1.142.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Poustchi H., Alaei-Shahmiri F., Aghili R. et al. Hepatic steatosis and fibrosis in type 2 diabetes: a risk-based approach to targeted screening. Arch. Iran. Med. 2021; 24 (3): 177-186. doi: 10.34172/aim.2021.28.</mixed-citation><mixed-citation xml:lang="en">Poustchi H., Alaei-Shahmiri F., Aghili R. et al. Hepatic steatosis and fibrosis in type 2 diabetes: a risk-based approach to targeted screening. Arch. Iran. Med. 2021; 24 (3): 177-186. doi: 10.34172/aim.2021.28.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chen K., Sng W. K., Quah J. H.-M. et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS One. 2020; 15 (8): e0236977. doi: 10.1371/journal.pone.0236977.</mixed-citation><mixed-citation xml:lang="en">Chen K., Sng W. K., Quah J. H.-M. et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS One. 2020; 15 (8): e0236977. doi: 10.1371/journal.pone.0236977.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Alfadda A. A., Sherbeeni S. M., Alqutub A. N. et al. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes. Saudi. J. Gastroenterol. 2022; 28: 426-433. doi: 10.4103/sjg.sjg_73_22.</mixed-citation><mixed-citation xml:lang="en">Alfadda A. A., Sherbeeni S. M., Alqutub A. N. et al. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes. Saudi. J. Gastroenterol. 2022; 28: 426-433. doi: 10.4103/sjg.sjg_73_22.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tuong T. T.K., Tran D. K., Phu P. Q.T. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using Fibroscan. Diagnostics. 2020; 10: 159. doi: 10.3390/diagnostics10030159.</mixed-citation><mixed-citation xml:lang="en">Tuong T. T.K., Tran D. K., Phu P. Q.T. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using Fibroscan. Diagnostics. 2020; 10: 159. doi: 10.3390/diagnostics10030159.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yu H., Su X., Tao W. et al. Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China. BMJ Open. 2024; 14: e087550. doi: 10.1136/bmjopen-2024-087550.</mixed-citation><mixed-citation xml:lang="en">Yu H., Su X., Tao W. et al. Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China. BMJ Open. 2024; 14: e087550. doi: 10.1136/bmjopen-2024-087550.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ciardullo S., Monti T., Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care. 2021; 44 (2): 519-525. doi: 10.2337/dc20-1778.</mixed-citation><mixed-citation xml:lang="en">Ciardullo S., Monti T., Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care. 2021; 44 (2): 519-525. doi: 10.2337/dc20-1778.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z. M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019; 71 (4): 793-801. doi: 10.1016/j.jhep.2019.06.021.</mixed-citation><mixed-citation xml:lang="en">Younossi Z. M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019; 71 (4): 793-801. doi: 10.1016/j.jhep.2019.06.021.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Huang N., Su X., Yu T. et al. Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China. Front. Endocrinol. 2024; 15: 1420088. doi: 10.3389/fendo.2024.1420088.</mixed-citation><mixed-citation xml:lang="en">Huang N., Su X., Yu T. et al. Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China. Front. Endocrinol. 2024; 15: 1420088. doi: 10.3389/fendo.2024.1420088.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ciardullo S., Muraca E., Cannistraci R. et al. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis. Diabetes Metab. Res. Rev. 2023; 39 (5): e3628. doi: 10.1002/dmrr.3628.</mixed-citation><mixed-citation xml:lang="en">Ciardullo S., Muraca E., Cannistraci R. et al. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis. Diabetes Metab. Res. Rev. 2023; 39 (5): e3628. doi: 10.1002/dmrr.3628.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Xing Y., Cheng T., Zhou F., Ma H. The association between vitamin D and type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease: an observational cross-sectional study. Diabetes Metab. Syndr. Obes. 2022; 15: 269-280. doi: 10.2147/DMSO.S348870.</mixed-citation><mixed-citation xml:lang="en">Xing Y., Cheng T., Zhou F., Ma H. The association between vitamin D and type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease: an observational cross-sectional study. Diabetes Metab. Syndr. Obes. 2022; 15: 269-280. doi: 10.2147/DMSO.S348870.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Li J., Ni Y. et al. Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients. BMC Endocrine Disorders. 2021; 21: 100. doi: 10.1186/s12902-021-00762-1.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Li J., Ni Y. et al. Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients. BMC Endocrine Disorders. 2021; 21: 100. doi: 10.1186/s12902-021-00762-1.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fang J.-X., Han Y., Meng J. et al. Relationship between non-alcoholic fatty liver and progressive fibrosis and serum 25-hydroxy vitamin D in patients with type 2 diabetes mellitus. BMC Endocrine Disorders. 2024; 24: 108. doi: 10.1186/s12902-024-01640-2.</mixed-citation><mixed-citation xml:lang="en">Fang J.-X., Han Y., Meng J. et al. Relationship between non-alcoholic fatty liver and progressive fibrosis and serum 25-hydroxy vitamin D in patients with type 2 diabetes mellitus. BMC Endocrine Disorders. 2024; 24: 108. doi: 10.1186/s12902-024-01640-2.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Cai J., Zhang Z., Liu J. et al. Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease. Exp. Ther. Med. 2020; 19 (3): 1681-1686. doi: 10.3892/etm.2020.8411</mixed-citation><mixed-citation xml:lang="en">Cai J., Zhang Z., Liu J. et al. Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease. Exp. Ther. Med. 2020; 19 (3): 1681-1686. doi: 10.3892/etm.2020.8411</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Stefan N., Schick F., Birkenfeld A. L. et al. The role of hepatokines in NAFLD. Cell. Metab. 2023; 35 (2): 236-252. doi: 10.1016/j.cmet.2023.01.006.</mixed-citation><mixed-citation xml:lang="en">Stefan N., Schick F., Birkenfeld A. L. et al. The role of hepatokines in NAFLD. Cell. Metab. 2023; 35 (2): 236-252. doi: 10.1016/j.cmet.2023.01.006.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Qin M., Zhong W. et al. RAGE promotes dysregulation of iron and lipid metabolism in alcoholic liver disease. Redox. Biol. 2023; 59: 102559. doi: 10.1016/j.redox.2022.102559.</mixed-citation><mixed-citation xml:lang="en">Li Y., Qin M., Zhong W. et al. RAGE promotes dysregulation of iron and lipid metabolism in alcoholic liver disease. Redox. Biol. 2023; 59: 102559. doi: 10.1016/j.redox.2022.102559.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gong L., Wei F., Gonzalez F. J. et al. Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology. 2023; 78 (5): 1625-1653. doi: 10.1097/HEP.0000000000000182.</mixed-citation><mixed-citation xml:lang="en">Gong L., Wei F., Gonzalez F. J. et al. Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology. 2023; 78 (5): 1625-1653. doi: 10.1097/HEP.0000000000000182.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Du T., Xiang L., Zhang J. et al. Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and b-oxidation. Front Endocrinol. 2023; 14 (8): 1138078. doi: 10.3389/fendo.2023.1138078.</mixed-citation><mixed-citation xml:lang="en">Du T., Xiang L., Zhang J. et al. Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and b-oxidation. Front Endocrinol. 2023; 14 (8): 1138078. doi: 10.3389/fendo.2023.1138078.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Yagoda A. V., Koroy P. V., Slyadnev S. A. positive correlation of the level of molecules of superfamily immunoglobulins icam-1, vcam-1 and pecam-1 with the index of fibrosis in nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2017; (2):45-51. (In Russ.)@@ Ягода А. В., Корой П. В., Сляднев С. А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138 (2):45-51.</mixed-citation><mixed-citation xml:lang="en">Yagoda A. V., Koroy P. V., Slyadnev S. A. positive correlation of the level of molecules of superfamily immunoglobulins icam-1, vcam-1 and pecam-1 with the index of fibrosis in nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2017; (2):45-51. (In Russ.)@@ Ягода А. В., Корой П. В., Сляднев С. А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138 (2):45-51.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade T. G., Xavier L. C.D., Souza F. F., Araújo R. C. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease - a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi: 10.20945/2359-3997000000514.</mixed-citation><mixed-citation xml:lang="en">Andrade T. G., Xavier L. C.D., Souza F. F., Araújo R. C. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease - a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi: 10.20945/2359-3997000000514.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Balaphas A., Meyer J., Sadoul K. et al. Platelets and platelet-derived extracellular vesicles in liver physiology and disease. Hepatol.Commun. 2019; 3 (7): 855-866. doi: 10.1002/hep4.1358.</mixed-citation><mixed-citation xml:lang="en">Balaphas A., Meyer J., Sadoul K. et al. Platelets and platelet-derived extracellular vesicles in liver physiology and disease. Hepatol.Commun. 2019; 3 (7): 855-866. doi: 10.1002/hep4.1358.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong L.-K., Zhang G., Lu S.-Y. et al. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J. Clin. Lab. Anal. 2020; 34 (7): e23270. doi: 10.1002/jcla.23270.</mixed-citation><mixed-citation xml:lang="en">Zhong L.-K., Zhang G., Lu S.-Y. et al. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J. Clin. Lab. Anal. 2020; 34 (7): e23270. doi: 10.1002/jcla.23270.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part - the multifaceted role of platelets in liver diseases.Int. J. Mol. Sci. 2021; 22: 3113. doi: 10.3390/ijms22063113.</mixed-citation><mixed-citation xml:lang="en">Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part - the multifaceted role of platelets in liver diseases.Int. J. Mol. Sci. 2021; 22: 3113. doi: 10.3390/ijms22063113.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Lu W., Li X., Liu N. et al. Vitamin D alleviates liver fibrosis by inhibiting histidine-rich calcium binding protein (HRC). Chem. Biol.Interact. 2021; 334: 109355. doi: 10.1016/j.cbi.2020.109355.</mixed-citation><mixed-citation xml:lang="en">Lu W., Li X., Liu N. et al. Vitamin D alleviates liver fibrosis by inhibiting histidine-rich calcium binding protein (HRC). Chem. Biol.Interact. 2021; 334: 109355. doi: 10.1016/j.cbi.2020.109355.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Roth C. L., Elfers C. T., Figlewicz D. P. et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012; 55 (4): 1103-1111. doi: 10.1002/hep.24737.</mixed-citation><mixed-citation xml:lang="en">Roth C. L., Elfers C. T., Figlewicz D. P. et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012; 55 (4): 1103-1111. doi: 10.1002/hep.24737.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Kwok R. M., Torres D. M., Harrison S. A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology. 2013; 58: 1166-1174. doi: 10.1002/hep.26390.Evividissulto es C. Dium.</mixed-citation><mixed-citation xml:lang="en">Kwok R. M., Torres D. M., Harrison S. A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology. 2013; 58: 1166-1174. doi: 10.1002/hep.26390.Evividissulto es C. Dium.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
